FuelCell Energy, Inc. (NASDAQ:FCEL) Up 7.39%, Echo Therapeutics Inc. (NASDAQ:ECTE) Up 7.20%
Northern, WI 05/24/2013 (GDPInsider) – FuelCell Energy, Inc. (NASDAQ:FCEL) is up 7.39% after a solid start in today’s trading of 1.19, 0.01 cent above its previous close of 1.18. FCEL has a range of 1.16 and 1.31 and volume activity is 3.515 million, more than double average volume of 1.171 million. The stock has shown an upward momentum and its technical chart shows a northward climb which began mid-April 2013. At present market valuation the stock is trading 10.07% below its 52-week high, but 50.60% above its 52-week low.
FCEL is coming off an announcement in April which detailed the sale of a megawatt-class fuel cell power plant for installation at Hartford Hospital in Hartford, Connecticut. The company will announce its second quarter 2013 financial results on June 6, 2013.
FCEL is overbought at present market valuation and has a RSI of 73.95. Its upward momentum however, means that trading values are up and FCEL is up 15.85% on its 20-day simple moving average and 25.10% on its 50-day simple moving average.
Is FCEL a solid investment at these levels? Get exclusive data and trends here.
Echo Therapeutics Inc. (NASDAQ:ECTE) started the day’s trading at 0.59, a clear 0.04 cents above its previous close of 0.55. The stock is up 7.20% on trading volume of 355.17K, 56.04% above average volume of 227.61K. ECTE has a range of 0.57 and 0.61 and the stock is trading 69.72% below its 52-week high of 2.00 and 236.44% above its 52-week low of 0.18.
The transdermal medical device company announced recently that its push to develop its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system has reached an advanced stage. ECTE unveiled Symphony CGM System during a live webcast at its annual shareholders meeting.
ECTE’s technical chart shows a southward slope with a marginal uptick in the last few trading sessions. The stock is up 12.57% on its SMA20 but down 6.69% on its SMA50. The stock has a healthy RSI of 56.92 indicating that it is neither oversold nor overbought at present market levels and analysts have set a target price of 2.92 for ECTE.
How Should Investors Trade ECTE Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.